New York, September 2021: Axiom Market Research & Consulting™ added a report on Anaphylaxis Treatment Market which includes study on allergy type, medication type, routes of administration, distribution channel, and geography. The Anaphylaxis Treatment Market was projected to grow at a CAGR of 8.27% for the forecast period 2021 to 2027. The global market is estimated and forecasted in terms of revenue (USD Million) generated by the Anaphylaxis Treatment Market.
The factors such as rising incidences of the anaphylaxis across the globe, along with the increasing innovative and novel product launches by some of the major companies, and the initiatives taken by the government for the reduction of cost and increasing number of the product approval have been responsible for the growth of the anaphylaxis treatment market during the forecast period. Although, the side effects caused due to the use of epinephrine and steroids along with lack of awareness in the developing regions are affecting the growth of the anaphylaxis treatment market.
The report analyses the anaphylaxis treatment market based on the allergy type, medication type, routes of administration, distribution channel, and geography. By allergy type, the anaphylaxis treatment is segmented into food allergy, medication, insect stings, and latex allergy. By medication type, the anaphylaxis treatment market is segmented into epinephrine, antihistamines, steroids, and beta-agonist. By routes of administration, the anaphylaxis treatment market is segmented into oral and parenteral. By distribution channel, the anaphylaxis treatment market is segmented into hospital pharmacies, retail sales, drug stores, and mail order pharmacies. By geography, the anaphylaxis treatment market is studied across the regions like North America, Europe, Asia Pacific and Rest of the World.
The food allergy is mainly caused when the immune system of the body that handles the harmless protein in the various foods as threat and it also releases different type of chemicals that are responsible for triggering the different types of the allergic reactions, attributing to the domination of the segment in the anaphylaxis treatment market.
The increasing cases of the food allergies and several other allergies owing to the immunomodulation in many patients has been propelling the growth of the anaphylaxis treatment market during the forecast period.
The epinephrine is a medication of choice for the first treatment of the anaphylaxis disease. By the effect of vasoconstriction, it helps in the decreasing the upper airway mucosal edema, shock and hypertensions. It also has significant effects of bronchodilator and cardiac inotropic effects.
The increasing patient football has been attributing the growth of the anaphylaxis treatment market over the forecast period, and the growing prevalence of the allergies has also been driving the growth of the anaphylaxis treatment market.
The increasing healthcare expenditure, along with increasing product launch and collaboration in some major key players and the increasing immunomodulation in the population has been fuelling the growth of the anaphylaxis treatment market in region of the North America.
The key players in the anaphylaxis treatment market are Amneal Pharmaceuticals Inc. (U.S.), Bioprojet (France), Mylan N.V. (U.S.), Adamis Pharmaceutical Corporation (San Diego), Abbott (U.S.), Pfizer Inc. (U.S.), GlaxoSmithKline Plc., (U.K.), Merck and Co., Inc. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel) and ALK-ABELLó (Denmark) among others.
Browse for More Details: https://www.axiommrc.com/product/11029-anaphylaxis-treatment-market-report
3 Germay Dr.Ste 4 - 4666
Wilmington DE 19804
U.S.:- + 1 (845) 875-9786
U.K.:- + 44 (0) 20 3286 9707